FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Drugs for Pulmonary/Respiratory Diseases in Phase I Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Voriconazole

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 19, 2020

            Details:

            Successfully completes single ascending dose phase of first clinical study in healthy subjects for a direct-to-lung, Thin Film Freezing (TFF) dry-powder formulation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Buprenorphine

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 27, 2020

            Details:

            BELBUCA effect on respiratory drive was comparable to placebo at all doses tested.The effect of immediate release oral oxycodone HCl resulted in a dose-dependent decrease in respiratory drive.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ifenprodil Tartrate

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 17, 2020

            Details:

            Algernon Pharma has appointed Novotech as the contract research organization for the its upcoming Phase 2 idiopathic pulmonary fibrosis and chronic cough study for the drug candidate NP-120.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PUR1800

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Nocion Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 06, 2020

            Details:

            The collaboration will leverage Pulmatrix's iSPERSE™ platform and expertise in seeking to transform promising assets to improve drug delivery and safety profiles.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PUR1800

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Johnson & Johnson Enterprise Innovation

            Deal Size: $100.2 million Upfront Cash: $7.2 million

            Deal Type: Licensing Agreement January 02, 2020

            Details:

            Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors,the intended for development in lung cancer interception. the ongoing Phase 1b study of RV1162/PUR1800 in stable COPD patients.